A Nettargets Inc. patent describes histone-lysine N-methyltransferase SETDB1 (KIAA0067, KMT1E) inhibitors reported to be useful for the treatment of cancer.
The first patenting from Fibra Inc. sees its founder and CEO Parnian Majid describe their development of a non-invasive wearable device which tracks fertility data through the measurement of various physiological parameters.
Neushen Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia, anxiety and post-traumatic stress disorder.
Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment of cancer.
Oregon Health and Science University (OHSU) and the Southern Research Institute have patented compounds reported to be useful for the treatment of alphaviral infections.
Nanjing Zaiming Pharmaceutical Co. Ltd. has described proteolysis targeting chimera (PROTACs) compounds comprising of E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker reported to be useful for the treatment of cancer.
Shanghai Yidi Biotechnology Co. Ltd. has patented dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or PDE4D2 inhibitors reported to be useful for the treatment of autoimmune, metabolic diseases, neurological and inflammatory disorders.
RSS
